A Phase Ill Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice as Second Line Treatment in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody in Combination With Platinum-based Chemotherapy
Latest Information Update: 31 Jul 2026
At a glance
- Drugs Izalontamab brengitecan (Primary) ; Docetaxel; Irinotecan; Paclitaxel
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms PANKU-Esophagus01
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 23 Jul 2026 Actual primary completion date changed to 17 Oct 2025.
- 23 Jul 2026 Planned End Date changed from 1 May 2026 to 1 Jun 2027.
- 17 Jul 2026 According to SystImmune media release, company has received regulatory approval from Chinas National Medical Products Administration (NMPA) for iza-bren (izalontamab brengitecan) for the treatment of adult patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) whose disease has progressed following prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy.